SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio” or the “Company”), a clinical-stage biotechnology company developing next-generation ...
AVEO Oncology, an LG Chem company, (AVEO) announced today that the first patient has been successfully dosed in a Phase 1b/2 clinical trial evaluating ficlatuzumab in combination with azacitidine and ...
Company to host analyst call at 5:00pm ET today to discuss progress to date and expansion of clinical trial SOUTH SAN ...
4d
SELLAS Life Sciences Enters Agreement with IMPACT-AML to Expand SLS009 Clinical Program into Europe
Supports capital-efficient expansion of the SLS009 clinical program into frontline AML, enabling broader U.S. and European patient enrollment ...
Research challenges age cut-offs in AML treatment, advocating for flexible, individualized approaches based on continuous age assessment. As patients age, their AML survival worsens, making age a ...
Omeros Corporation (Nasdaq: OMER) today announced the establishment of the Omeros Oncology Clinical Steering Committee to advance Omeros’ OncotoX biologics program focused on acute myeloid leukemia ...
SEATTLE, WA / ACCESS Newswire / June 18, 2025 / Aptevo Therapeutics ("Aptevo") (Nasdaq:APVO), a clinical-stage biotechnology company developing novel bispecific immuno-oncology therapeutics based on ...
SENTI-202, an off-the-shelf CAR NK cell therapy for AML, received FDA orphan drug designation, supporting its development for relapsed or refractory cases. LYL314, a CAR T-cell therapy for large ...
The MarketWatch News Department was not involved in the creation of this content. No dose-limiting toxicities or cytokine release syndrome observed in RAINIER to date; mipletamig shows consistently ...
– The Steering Committee brings together distinguished clinical experts in AML from leading National Comprehensive Cancer Network Centers – SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today ...
CEO Troy Wilson highlighted significant progress in clinical and regulatory milestones, including the submission of a New Drug Application (NDA) for ziftomenib as a monotherapy for relapsed/refractory ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback